Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Cancer
Intervention:   Biological: CD137L-DC-EBV-VAX
Sponsor:   National University Hospital, Singapore
Recruiting - verified September 2017

http://ift.tt/2xBwoCu